Caregen Co (214370) Fair Value & Analysis
Healthcare · KR · Market cap 3.8T KRW
Fair value as of: Jul 7, 2026
From 25 valuation models · updated yesterday
Fair value updated Jul 7, 2026 — revised from 6,835 KRW to 7,277 KRW (+6.5%) since Jun 24, 2026. Share price −12.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 30,071 KRW – 150,760 KRW · fair‑value band 5,177 KRW – 9,052 KRW · the 68,500 KRW price screens above the 7,277 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Caregen Co (214370) currently trades at 68,500 KRW, while our model-based Fair Value estimate is 7,277 KRW — implying the stock looks roughly 89.4% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Caregen Co generated revenue of 65.0B KRW at a net margin of 39.6%. Revenue grew 34.2% year over year. Fundamentals as of Jul 7, 2026
Our scenario range runs from 5,177 KRW (bear case) to 9,052 KRW (bull case); at 68,500 KRW, the current price sits above that range. The share trades about 55% below its 52-week high and 132% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -15% fair-value upside — at -89%, 214370 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG Styler 600 names. The company's products are used in anti-aging, anti-pigmentation, anti-hair loss, anti-inflammation, and other skin troubles, as well as blood sugar control, baby skin care, and acute muscle pain applications. In addition, its products in pipeline include pharmaceuticals in the areas of wet and dry macular degeneration, diabetic retinopathy, cataract, hyperhidrosis, pain relief, obesity, psoriasis, scar, arthritis, rhinitis, anti-virus, and Covid-19 treatment; and medical devices for face beauty treatment, scalp and hair improvement, body care, arthritis, and new face …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Caregen Co reported revenue of 72.8B KRW in FY2025 versus 59.1B KRW in FY2021, a compound +5.4%/yr. Reported net income was 20.1B KRW in FY2025, compounding −5.6%/yr from FY2021.
Is 214370 fairly valued? → Check now
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| ST Pharm Co 237690 | 115,900 KRW | 61,182 KRW | -47% |
| NatureCell Co 007390 | 30,800 KRW | 901.89 KRW | -97% |
| Oscotec Inc 039200 | 34,700 KRW | 20,830 KRW | -40% |
| DongKook Pharmaceutical Co 086450 | 18,940 KRW | 20,299 KRW | +7% |
| Kolon Life Science Inc 102940 | 43,600 KRW | 37,195 KRW | -15% |
| BINEX Co 053030 | 6,900 KRW | 27,024 KRW | +292% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 22,700 KRW | 49,475 KRW | +118% |
| Vivozon Pharmaceutical Co 082800 | 4,045 KRW | 1,992 KRW | -51% |
| EURO EURO | 1.07 PHP | 0.7800 PHP | -27% |
| Kyung Dong Pharmaceutical Co 011040 | 4,805 KRW | 6,187 KRW | +29% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Caregen Co (214370) undervalued?
What is the fair value of 214370?
What is the quality score of 214370?
What is the revenue of Caregen Co (214370)?
What is the net profit margin of 214370?
Does Caregen Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.